2025 Speakers

Ester Sklarsky is an investment professional in life sciences, currently at Sound Bioventures, a Scandinavian biotech venture capital fund. Prior to joining the firm, she spent over two years at Industrifonden, where she worked across the investment lifecycle, managing deal flow and performing scientific and strategic due diligence for early-stage biotech ventures.
Ester began her career in management consulting at Sirona Health Solutions, advising key stakeholders in the Swedish public healthcare sector. She also gained experience as an equity analyst at DNB, with a dedicated focus on the biotech sector.
She holds a B.Sc. in Biomedicine and an M.Sc. in Bioentrepreneurship, both from the Karolinska Institute in Stockholm.

Gemma is Principal at Invivo Partners, a Spanish venture capital firm based in Barcelona, focused on early-stage investments and technology transfer in innovative areas of drug development. Invivo Partners manages three VC funds, including its first fund, Healthequity, launched in 2012, a second fund raised in 2019 with €60M under management and a third fund launched in 2024 targeting 100M€. Backed by a majority of private investors and supported by institutions such as the European Investment Fund, Fond-ICO Global, the Catalan Finance Institute, the Valencia Institute of Finance, and the Barcelona City Council, Invivo Partners seeks opportunities across Europe and leverages a strong co-investment network.

Previously, Gemma was a Project Manager at UPF Ventures. She holds a BSc in Biomedical Sciences from the University of Barcelona, an MSc in Business Management Applied to Biotechnology from the Biotechnology Business Institute, and a Postgraduate Certificate in Financial Management from UPF Barcelona School of Management. She currently serves as a Board Observer at Telomere Therapeutics, EsoBiotec, Integra Therapeutics, Telum Therapeutics, Peptomyc, and Signadori Bio.